Mentorship for Addiction Problems (MAP): A New Behavioral Intervention to Assist in the Treatment of Substance Use Disorders.


Journal

Journal of studies on alcohol and drugs
ISSN: 1938-4114
Titre abrégé: J Stud Alcohol Drugs
Pays: United States
ID NLM: 101295847

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 5 1 2021
Statut: ppublish

Résumé

Mentorship for Addiction Problems (MAP) is a new behavioral treatment formalizing client-to-client mentorship relationships as an adjunct to standard outpatient substance use disorder treatment. We tested the preliminary efficacy of MAP in reducing substance use and associated barriers to successful treatment outcomes. A total of 65 participants (17 later recovery participants [LRPs] and 48 early recovery participants [ERPs]) with substance use disorders were randomized to MAP + Treatment as Usual (TAU) or TAU alone. Within MAP, for each cohort, a pool of 4-5 mentors (LRPs) was formed and engaged in mentoring activities for 24 weeks until 12-13 mentees (ERPs), newly admitted, had participated in MAP for 12 weeks. Behavioral and biological measures were conducted at baseline, weekly, monthly, and termination for all participants and during the 12-week follow-up for ERPs. Substance use declined across both conditions for ERPs (N = 48) during treatment, Weeks 0-12 (p = .001); however, on average, ERPs in the MAP intervention used significantly fewer days than controls during Treatment Weeks 1-12 (p = .013) and during Follow-Up Weeks 13-24 (p = .043). Addiction Severity Index alcohol and drug use scores increased in TAU and decreased in MAP during Follow-Up Weeks 13-24 for ERPs, alcohol: b = -0.08, SE = 0.03, t(47) = -2.97, p = .005; drug use: b = -0.02, SE = 0.01, t(47) = -2.36, p = .023. In addition, there was high patient interest in MAP and good fidelity to delivery of treatment. MAP shows promise assisting in the reduction of substance use early in treatment when vulnerability and risk for relapse is high and has a positive impact on serious problems undercutting addiction treatment efficacy.

Identifiants

pubmed: 33028480
pmc: PMC8076492

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

664-672

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA016160
Pays : United States
Organisme : NIDA NIH HHS
ID : R34 DA034898
Pays : United States

Déclaration de conflit d'intérêts

There are no conflicts of interest within this study.

Références

J Subst Abuse Treat. 1996 Nov-Dec;13(6):533-6
pubmed: 9219152
Psychiatry Res. 2017 Jun;252:1-8
pubmed: 28237758
Compr Psychiatry. 1994 Jul-Aug;35(4):316-27
pubmed: 7956189
Epidemiol Psychiatr Sci. 2016 Apr;25(2):113-22
pubmed: 26744309
J Stud Alcohol. 2002 Sep;63(5):534-41
pubmed: 12380849
Am J Drug Alcohol Abuse. 1991;17(1):89-101
pubmed: 1645496
Behav Res Ther. 1976;14(5):339-48
pubmed: 971207
Exp Clin Psychopharmacol. 2001 Feb;9(1):14-23
pubmed: 11519628
Am J Public Health. 2005 Mar;95(3):518-24
pubmed: 15727987
MMWR Morb Mortal Wkly Rep. 2012 Jan 13;61(1):10-3
pubmed: 22237030
Addiction. 1997 Dec;92(12):1671-98
pubmed: 9581001
Psychiatr Serv. 2008 Nov;59(11):1307-14
pubmed: 18971407
Clin Psychol Psychother. 2011 Jan-Feb;18(1):75-9
pubmed: 20309842
AIDS. 2012 Jun 19;26(10):1205-13
pubmed: 22706007
Heart Lung. 2008 Sep-Oct;37(5):334-43
pubmed: 18790334
Psychol Addict Behav. 2014 Mar;28(1):154-62
pubmed: 23276315
Natl Vital Stat Rep. 2019 Jun;68(9):1-77
pubmed: 32501199
Drug Alcohol Depend. 2019 Sep 1;202:134-148
pubmed: 31349206
Psychother Psychosom. 2009;78(5):275-84
pubmed: 19602916
Community Ment Health J. 2015 May;51(4):393-403
pubmed: 25022913
J Consult Clin Psychol. 1999 Oct;67(5):688-97
pubmed: 10535235
J Child Psychol Psychiatry. 2019 Apr;60(4):455-472
pubmed: 29900543
Subst Abuse Rehabil. 2016 Sep 29;7:143-154
pubmed: 27729825
J Affect Disord. 2019 Aug 1;255:127-135
pubmed: 31150942
Psychiatr Serv. 1998 Apr;49(4):533-5
pubmed: 9550249
J Stud Alcohol. 2003 Mar;64(2):257-61
pubmed: 12713200
J Consult Clin Psychol. 2000 Feb;68(1):64-72
pubmed: 10710841
J Subst Abuse Treat. 2018 Dec;95:26-34
pubmed: 30352667
Drug Alcohol Depend. 1986 Dec;18(4):341-8
pubmed: 3816530
J Nerv Ment Dis. 1985 Jul;173(7):412-23
pubmed: 4009158
J Consult Clin Psychol. 2002 Oct;70(5):1182-5
pubmed: 12362968
J Ment Health. 2016;25(1):78-86
pubmed: 26397981
Alcohol Alcohol. 2012 Jan-Feb;47(1):42-7
pubmed: 22045903
J Subst Abuse Treat. 2016 Apr;63:1-9
pubmed: 26882891
J Subst Abuse Treat. 2004 Apr;26(3):225-32
pubmed: 15063917
Alcohol Res Health. 1999;23(2):116-21
pubmed: 10890805
Am J Community Psychol. 2002 Apr;30(2):245-70
pubmed: 12002245

Auteurs

Kathlene Tracy (K)

Psychosocial Division, Addiction Institute Mount Sinai (AIMS), Laboratory of Psychosocial Processes in Addiction, Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, New York.

Leah Wachtel (L)

Psychosocial Division, Addiction Institute Mount Sinai (AIMS), Laboratory of Psychosocial Processes in Addiction, Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, New York.

Emily Goldmann (E)

College of Global Public Health, New York University, New York, New York.

Joseph Nissenfeld (J)

Division of Alcoholism and Drug Abuse, New York University School of Medicine, Department of Psychiatry, New York, New York.

Mark Burton (M)

Division of Alcoholism and Drug Abuse, New York University School of Medicine, Department of Psychiatry, New York, New York.

Marc Galanter (M)

Division of Alcoholism and Drug Abuse, New York University School of Medicine, Department of Psychiatry, New York, New York.

Samuel A Ball (SA)

Yale University School of Medicine, Department of Psychiatry, New Haven, Connecticut.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH